NCT00607152View on ClinicalTrials.gov

Rasburicase (Fasturtec) Registration Trial

PHASE3TerminatedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Hyperuricemia

Interventions

DRUG

Rasburicase

0.20mg/kg per day IV

DRUG

Allopurinol

100mg tablets

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY